Loading clinical trials...

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

Determination of Optimal Dose and Safety Profile of Optison Ultrasound Contrast Agent in Pediatric Solid Tumor Patients

NCT00186953•St. Jude Children's Research Hospital

Summary

St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's Research Hospital researchers want to learn the best and safest dose of this ultrasound "dye."

Eligibility

Age

2 - 20 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age: 2-20 years old
•Subject has a known or suspected solid soft tissue tumor in the abdomen or pelvis.
•Subject is scheduled for other imaging or is already scheduled for an ultrasound or has already had adequate imaging performed at an outside institution.
•Subject is able to lie still for the exam without sedation.

Exclusion Criteria

•Known or suspected hypersensitivity to albumin, blood or blood products.
•History of open heart surgery, cyanotic congenital heart disease or an axygen saturation of less than 96% as determined by pulse oximetry.

Locations (1)

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Key Dates

Start Date

June 1, 2002

Primary Completion Date

August 1, 2004

Completion Date

August 1, 2004

Last Updated

September 20, 2011

Enrollment

ACTUAL participants

Conditions

Abdominal NeoplasmsPelvic Neoplasms

Interventions

Optison

DRUG

Augmented Pulse Pressure Variation to Predict Fluid Responsiveness in Open Laparotomy

NCT02653469

Gynecologic NeoplasmsAbdominal Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 20, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions